Hollingshead James
Hollingshead James's purchase track record
Hollingshead James has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/28/2023 | PODD | $1.01M | +3.6% | -6.8% | +14.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
ResMed Q4 2026 Earnings Call Transcript Released. ResMed has released the transcript for its Q4 2026 earnings call, providing investors with detailed insights into the company's recent performance. This follows a quarterly earnings preview and places the stock within a broader market forecast for the mHealth sector. The release offers a factual record of management's comments on financial results and strategic direction.
Transaction History
| PODD | ▼ Sell | Tax Withholding | 3,587 | $931K | 4/28/2025 | View on chart |
| PODD | ▼ Sell | Tax Withholding | 1,160 | $316K | 2/28/2025 | View on chart |
| PODD | ▼ Sell | Tax Withholding | 2,074 | $554K | 2/27/2025 | View on chart |
| PODD | ▲ Buy | Grant | 7,687 | $0 | 2/25/2025 | View on chart |
| PODD | ▲ Buy | Grant | 36,671 | $0 | 2/17/2025 | View on chart |
| PODD | ▼ Sell | Tax Withholding | 18,019 | $5.1M | 2/17/2025 | View on chart |
| PODD | ▼ Sell | Tax Withholding | 3,973 | $704K | 5/31/2024 | View on chart |
| PODD | ▼ Sell | Tax Withholding | 908 | $149K | 2/28/2024 | View on chart |
| PODD | ▲ Buy | Grant | 12,303 | $0 | 2/27/2024 | View on chart |
| PODD | ▲ Buy | Open Market | 5,550 | $1.0M | 8/28/2023 | View on chart |
| PODD | ▼ Sell | Tax Withholding | 3,898 | $1.1M | 6/1/2023 | View on chart |
| PODD | ▲ Buy | Grant | 6,875 | $0 | 2/28/2023 | View on chart |
| PODD | ▲ Buy | Grant | 21,699 | $0 | 6/1/2022 | View on chart |
| RMD | ▼ Sell | Open Market | 2,400 | $616K | 12/1/2021 | View on chart |
| RMD | ▲ Buy | Grant | 316 | $0 | 11/18/2021 | View on chart |
| RMD | ▲ Buy | Grant | 1,393 | $0 | 11/18/2021 | View on chart |
| RMD | ▼ Sell | Tax Withholding | 12,060 | $3.1M | 11/17/2021 | View on chart |
| RMD | ▲ Buy | Grant | 20,360 | $5.2M | 11/16/2021 | View on chart |
| RMD | ▼ Sell | Tax Withholding | 4,100 | $1.1M | 11/11/2021 | View on chart |
| RMD | ▼ Sell | Open Market | 2,400 | $634K | 11/1/2021 | View on chart |
| RMD | ▼ Sell | Tax Withholding | 234 | $58K | 10/8/2021 | View on chart |
| RMD | ▼ Sell | Open Market | 2,400 | $627K | 10/1/2021 | View on chart |
| RMD | ▼ Sell | Open Market | 2,400 | $690K | 9/1/2021 | View on chart |
| RMD | ▲ Buy | Grant | 5,741 | $0 | 8/19/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Insulet Sets Q3 2026 Earnings Date for Nov 4
Insulet has scheduled its third-quarter 2026 financial results for release on November 4, 2026. Recent commentary suggests the company offers affordable growth supported by strong fundamentals. The stock is currently trading near its 52-week low, with technical indicators showing a support rejection and volume spike.
Insulet Sets Q3 2026 Earnings Date for Nov 4. Insulet has scheduled its third-quarter 2026 financial results for release on November 4, 2026. Recent commentary suggests the company offers affordable growth supported by strong fundamentals. The stock is currently trading near its 52-week low, with technical indicators showing a support rejection and volume spike.